Document/ExhibitDescriptionPagesSize 1: 8-K Current Report HTML 36K
2: EX-99.1 Miscellaneous Exhibit HTML 22K
6: R1 Document and Entity Information Document HTML 45K
8: XML IDEA XML File -- Filing Summary XML 11K
11: XML XBRL Instance -- isrg-20240314_htm XML 13K
7: EXCEL IDEA Workbook of Financial Report Info XLSX 8K
4: EX-101.LAB XBRL Labels -- isrg-20240314_lab XML 64K
5: EX-101.PRE XBRL Presentations -- isrg-20240314_pre XML 34K
3: EX-101.SCH XBRL Schema -- isrg-20240314 XSD 10K
9: JSON XBRL Instance as JSON Data -- MetaLinks 12± 18K
10: ZIP XBRL Zipped Folder -- 0001035267-24-000125-xbrl Zip 21K
(Address of Principal Executive Offices) (Zip Code)
Registrant’s telephone number, including area code: (i408)
i523-2100
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
i☐
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
i☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
i☐
Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
i☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
iCommon
Stock, par value $0.001 per share
iISRG
iThe Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company i☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 7.01.
Regulation
FD Disclosure.
On March 14, 2024, Intuitive Surgical, Inc. (“Intuitive”) issued a press release announcing U.S. Food and Drug Administration clearance of its fifth-generation robotic system, da Vinci 5. A copy of the press release is furnished hereto as Exhibit 99.1.
Intuitive will hold a teleconference at 5:45 a.m. PDT on Monday, March 18, 2024, to discuss the da Vinci 5 features and benefits and our launch plans. The call will be webcast and can be accessed on Intuitive's website
at www.intuitive.com or by dialing (844) 291-6362 using the access code 5898411. The webcast replay of the call will be made available on our website at www.intuitive.com within 24 hours after the end of the live teleconference and will be accessible for at least 30 days.
The information in this Current Report on Form 8-K, including Exhibit
99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities under that section and shall not be deemed to be incorporated by reference into any filing of Intuitive under the Securities Act of 1933, as amended, or the Exchange Act.
Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
